- Home
- ARMN vs SRPT Comparison
ARMN vs SRPT Comparison
Compare ARMN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- SRPT
- Stock Information
- Founded
- ARMN 1992
- SRPT 1980
- Country
- ARMN Canada
- SRPT United States
- Employees
- ARMN N/A
- SRPT N/A
- Industry
- ARMN
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- SRPT Health Care
- Exchange
- ARMN Nasdaq
- SRPT Nasdaq
- Market Cap
- ARMN 2.0B
- SRPT 1.9B
- IPO Year
- ARMN N/A
- SRPT 1997
- Fundamental
- Price
- ARMN $9.79
- SRPT $17.65
- Analyst Decision
- ARMN Strong Buy
- SRPT Hold
- Analyst Count
- ARMN 1
- SRPT 30
- Target Price
- ARMN $17.00
- SRPT $35.93
- AVG Volume (30 Days)
- ARMN 1.1M
- SRPT 6.0M
- Earning Date
- ARMN 10-29-2025
- SRPT 11-03-2025
- Dividend Yield
- ARMN N/A
- SRPT N/A
- EPS Growth
- ARMN N/A
- SRPT N/A
- EPS
- ARMN 0.26
- SRPT N/A
- Revenue
- ARMN $770,175,000.00
- SRPT $2,413,715,000.00
- Revenue This Year
- ARMN $73.48
- SRPT $10.20
- Revenue Next Year
- ARMN $56.35
- SRPT N/A
- P/E Ratio
- ARMN $39.60
- SRPT N/A
- Revenue Growth
- ARMN 58.96
- SRPT 47.15
- 52 Week Low
- ARMN $3.29
- SRPT $10.42
- 52 Week High
- ARMN $11.24
- SRPT $138.81
- Technical
- Relative Strength Index (RSI)
- ARMN 50.17
- SRPT 38.30
- Support Level
- ARMN $9.57
- SRPT $15.08
- Resistance Level
- ARMN $10.04
- SRPT $18.80
- Average True Range (ATR)
- ARMN 0.49
- SRPT 1.40
- MACD
- ARMN -0.05
- SRPT -0.84
- Stochastic Oscillator
- ARMN 58.81
- SRPT 24.92
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development, and operation of gold properties in Colombia, Guyana, and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, the Toroparu Project in Guyana, and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.